Platina
Plasmids,
Inc.
Aomori,
Japan
News
| 12 Oct 2024 | We have participated in BioJapan 2024. |
|---|---|
| 30 May 2024 | Our HP is now open! |
Overview
PlatinaPlasmids, Inc. is a bio-venture start-up originated from Professor Hodaka Fujii lab at Hirosaki University Graduate School of Medicine founded in 2023.
Some plasmids used in gene therapy, mRNA vaccine production, etc. can be difficult to propagate because of repetitive sequences and other factors. Our proprietary technology enables mass amplification of such problematic plasmids.
Utilizing such basic biotechnologies, we can support the state-of-the-art medicine and contribute to proliferation of health and wealth of human beings.
Business Activities
PlatinaPlasmids, Inc.
provides plasmids whose
amplification in E. coli is very difficult.
Gene therapy and development of mRNA vaccines need high quality DNA. Plasmid DNAs are the major source and amplified in E. coli in general. However, such plasmids containing repetitive and other problematic sequences often recombine, making it difficult to amplify plasmids of intended correct sequences.
PlatinaPlasmids, Inc. retains proprietary technologies enabling stable amplification of such problematic plasmids that are difficult to be amplified in widely used E. coli strains. We provide amplified plasmids to pharma and academia.
Using such biotechnologies, we support state-of-the-art medicine and contribute to proliferation of health and wealth of human beings.
Other pre-existing technologies
1. Use of E. coli strains lacking genes involved in genetic recombination
E. coli strains lacking genes involved in genetic recombination are widely used to avoid recombination of plasmids. However, it is often difficult to completely avoid generation of recombinants.
[ features ]
- No colonies
- Only recombinants are obtained
2. In vitro DNA amplification methods such as PCR
In vitro DNA amplification methods such as PCR and LAMP enable amplification of DNA fragments. However, it is not suitable for generation of large amounts of DNA (≥ mg order) because of high cost and labor. In addition, these methods suffer from high replication error rates. Since wrong DNA sequences can contaminate samples, their use in preparation of DNA for gene therapies and other clinical application should be avoided.
[ features ]
- Not suitable for large scale preparation
- Frequent replication errors
3. In vitro amplification of plasmids
By inserting a sequence of a replication origin into a plasmid, it can be amplified in vitro. However, it takes time and effort to make such plasmids. In addition, it costs a lot to generate large amounts of DNA (≥ mg order) .
[ features ]
- In vitro reconstitution of plasmid replication machinery
- Insertion of a replication origin sequence necessary
- Costly for largen scale preparation
- High rate of mutations
Our strengths
Our proprietary technology can avoid recombination or other disastrous changes in plasmids in E. coli. Since plasmids can be amplified in E. coli, large scale production of plasmids can be achieved economically.
Compared to in vitro DNA fragment / plasmid amplification, it is not necessary to insert an additional replication origin, and widely used plasmid vector can be directly used. Therefore, labor is less, cost is much lower, and yields are much larger.
Please place orders for amplification of plasmids for research use through Funakoshi Co. Ltd.
If you have plan to use plasmids for non-research use such as production of drugs, please contact us directly.
Contact UsAbout PlatinaPlasmids
| Company Name | PlatinaPlasmids, Inc. |
|---|---|
| Headquarter Location | 3-7-14 Waseda, Hirosaki, Aomori 036-8087, JAPAN |
| Date of Establishment | August 4, 2023 |
| Management | Hodaka Fujii, M.D., Ph.D. |
| Scope of Business | Research & Development, Manufacturing, Sales & Marketing, Import & Export of Pharmaceutical Drugs, etc. |